Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor that works by blocking the enzyme that degrades cyclic GMP (cGMP). Elevated cGMP relaxes vascular smooth muscle, increasing blood flow. It is FDA-approved under the brand names Viagra (erectile dysfunction, 1998) and Revatio (pulmonary arterial hypertension, 2005).

What dose of sildenafil is used for erectile dysfunction?

For erectile dysfunction, the typical starting dose is 50mg taken 30-60 minutes before sexual activity. The dose can be adjusted to 25mg (lower sensitivity or drug interactions) or 100mg (if 50mg insufficient). It should not be taken more than once per 24 hours.

Does sildenafil improve athletic performance?

Evidence is mixed. At altitude (above 3000m), sildenafil consistently reduces high-altitude pulmonary edema and improves exercise capacity by reducing hypoxic pulmonary vasoconstriction. At sea level, randomized controlled trials generally show no meaningful performance improvement in healthy athletes. Benefits appear altitude- and hypoxia-dependent.

Can sildenafil be combined with tadalafil?

Combining two PDE5 inhibitors is not recommended and increases risk of hypotension. They should not be used together. Both are contraindicated with nitrates (nitroglycerin, poppers) due to severe hypotension risk. Tadalafil is preferred for daily use due to its longer half-life (17-21 hours vs 3-5 hours for sildenafil).

PDE5 Inhibitor • Vasodilator • FDA Approved

Sildenafil: The Vasodilator Beyond the Blue Pill

By MeetPeptide Research Team

Last updated: March 2026

Sildenafil (Viagra/Revatio) is an FDA-approved PDE5 inhibitor with well-established efficacy in erectile dysfunction and pulmonary arterial hypertension. Research also explores its utility for altitude sickness, exercise performance at altitude, Raynaud's phenomenon, and heart failure. 25-100mg oral.

Oral Dose Range
ED Indication

Erectile Function Response
50mg in Phase 3 Trials

Year FDA Approved
First PDE5 Inhibitor

Mechanism of Action

How Sildenafil Works

Sildenafil selectively inhibits PDE5 — the enzyme that breaks down cyclic GMP (cGMP). In vascular smooth muscle, cGMP activates protein kinase G, which relaxes smooth muscle cells and dilates blood vessels. Sildenafil doesn't directly cause erection — it potentiates the cGMP signal that sexual stimulation produces via nitric oxide (NO) release.

🔬

NO → cGMP → PDE5 Pathway

Sexual stimulation triggers nitric oxide (NO) release from penile endothelium and nerve endings. NO activates soluble guanylate cyclase, producing cGMP from GTP. cGMP relaxes cavernous smooth muscle, allowing blood flow into the corpus cavernosum. PDE5 normally degrades cGMP and ends the response. Sildenafil blocks PDE5, prolonging and amplifying the cGMP signal — but only when NO is present.

🫁

Pulmonary Vasodilation — PAH Mechanism

In pulmonary arterial hypertension (PAH), chronically elevated pulmonary vascular resistance strains the right ventricle. Sildenafil (as Revatio, 20mg TID) selectively dilates pulmonary vasculature by blocking PDE5 — which is highly expressed in lung tissue. This reduces pulmonary vascular resistance, decreases right heart afterload, and improves 6-minute walk distance. The SUPER-1 trial showed ~45m improvement in 6MWD.

🏔️

Altitude & Hypoxia Application

At high altitude, hypoxia triggers pulmonary vasoconstriction (hypoxic pulmonary vasoconstriction, HPV) — the same mechanism that drives PAH. Sildenafil reduces this vasoconstriction, lowering pulmonary artery pressure and reducing the risk of high-altitude pulmonary edema (HAPE). Studies at 3500-5182m show sildenafil improves exercise capacity and reduces pulmonary pressures in subjects exposed to hypoxia.

🩸

Raynaud's & Peripheral Vascular Effects

PDE5 is expressed in peripheral vascular smooth muscle, and sildenafil reduces peripheral vascular resistance. In Raynaud's phenomenon, where digital arteries vasospasm in response to cold or stress, sildenafil reduces attack frequency and severity. Meta-analyses show ~34% reduction in Raynaud's attack frequency. It's also being studied in systemic sclerosis (scleroderma) with associated digital ulcers.

Research Data

What the Clinical Trials Show

Data from pivotal Phase 3 trials across indications. ED data from original Pfizer trials (1998); PAH from SUPER-1 (2005); altitude from Richalet et al. and similar controlled studies.

Erectile Function Response Rate (50mg)

Men reporting improved erections in pivotal Phase 3 ED trial

~69%

Successful Intercourse Attempts (50mg)

~57% sildenafil vs ~21% placebo — pivotal ED trial

57% vs 21%

6-Minute Walk Distance Improvement (PAH)

SUPER-1 trial: 20mg TID in PAH — mean increase in 6MWD

+45m

Pulmonary Arterial Pressure Reduction (PAH)

SUPER-1: mean reduction in mean PAP with 20mg TID

~3.0 mmHg

Raynaud's Attack Frequency Reduction

Meta-analysis of sildenafil in Raynaud's — attack rate reduction

~34%

Safety Profile

Side Effects & Risks

Adverse event incidence from pivotal Phase 3 ED trials (50mg dose). Sildenafil is contraindicated with nitrates — this interaction can cause fatal hypotension.

Headache

Most common side effect — vasodilation of cerebral vessels

~16%

Flushing

Cutaneous vasodilation — typically mild and transient

~10%

Dyspepsia / Indigestion

GI smooth muscle relaxation effect

~7%

Nasal Congestion

Nasal mucosal vasodilation

~4%

Visual Color Disturbance (Blue Tinge)

PDE6 cross-reactivity in retinal photoreceptors — transient

~3%

Bottom Line

Key Takeaways

✅ What We Know

FDA-approved for ED (Viagra, 1998) and PAH (Revatio, 2005) — extensive safety record
~69% response rate for ED at 50mg — the benchmark PDE5 inhibitor
Proven benefit in pulmonary arterial hypertension — SUPER-1 trial confirmed
Effective for altitude-related pulmonary hypertension — reduces HAPE risk
Reduces Raynaud's attack frequency ~34% — well-supported by meta-analyses
3-5 hour half-life — shorter-acting than tadalafil, taken as-needed for ED

⚠️ What We Don't Know

Performance benefits at sea level are not established — altitude-specific
Optimal dosing for cardiac and heart failure applications still being studied
Long-term daily use effects beyond current PAH trial durations
Interaction profile with newer cardiovascular medications evolving
Combination with PT-141 or other sexual health peptides — limited data

📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.

Get the Guide →

⚠️ Important Disclaimer

This page is for educational purposes only. Sildenafil is an FDA-approved prescription medication. It is contraindicated with nitrates (nitroglycerin, isosorbide, amyl nitrite/"poppers") — this combination can cause life-threatening hypotension. Always consult a licensed healthcare provider before use. Do not self-prescribe. This is not medical advice.